HC Wainwright Reiterates Neutral Recommendation on Co-Diagnostics with 482.52% Upside Potential.

Monday, Nov 24, 2025 11:23 pm ET1min read

HC Wainwright & Co. reiterated its coverage of Co-Diagnostics with a Neutral recommendation. Analysts forecast an average one-year price target of $2.04/share, a 482.52% increase from its latest closing price of $0.35/share. The projected annual revenue for Co-Diagnostics is $2MM, a 201.25% increase, and the projected annual non-GAAP EPS is 0.38.

HC Wainwright Reiterates Neutral Recommendation on Co-Diagnostics with 482.52% Upside Potential.

Aime Insights

Aime Insights

Which companies have consistent earnings growth and high profit margins?

What dividend aristocrats would you suggest for stable income?

How do profit margins compare among leading social media companies over the past five years?

How is the S&P 500 performing today, and could you explain the reasons behind it?

Comments



Add a public comment...
No comments

No comments yet